Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study-Reference-Cited by-同舟云学术

Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study

Published:2024-05-17 Issue:8 Volume:29 Page:1142-1151
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Nosaki Kaname,Yoh Kiyotaka^ORCID,Toyozawa Ryo,Horinouchi Hidehito,Morise Masahiro,Ohashi Kadoaki,Murakami Haruyasu,Satouchi Miyako,Sakakibara-Konishi Jun,Yano Seiji,Okumura Fumihiko,Matsumoto Shingo,Shimokawa Mototsugu,Seto Takashi,Goto Koichi

Funder

Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02543-x.pdf

Reference27 articles.

1. National Comprehensive Cancer Network (2023) In: Proceedings of the NCCN Clinical Practice Guidelines in Oncology—Non-Small Cell Lung Cancer, Plymouth, PA, USA

2. Kawakami H, Okamoto I, Okamoto W et al (2014) Targeting MET Amplification as a New Oncogenic Driver. Cancers (Basel) 6(3):1540–1552. https://doi.org/10.3390/cancers6031540

3. Kong-Beltran M, Seshagiri S, Zha J et al (2006) Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66(1):283–289. https://doi.org/10.1158/0008-5472.CAN-05-2749

4. Frampton GM, Ali SM, Rosenzweig M et al (2015) Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5(8):850–859. https://doi.org/10.1158/2159-8290.CD-15-0285

5. Awad MM, Oxnard GR, Jackman DM et al (2016) MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression. J Clin Oncol 34(7):721–730. https://doi.org/10.1200/JCO.2015.63.4600